Nasal moisturizers
This article was originally published in The Tan Sheet
Executive Summary
Nasal moisturizers should be removed from FDA's OTC product review and regulated as cosmetics, law firm Kirkpatrick & Lockhart (Washington, D.C.) maintains in comments to FDA. Claims that the products provide moisture for inflamed nasal membranes due to colds "is not indicating a treatment for the cold, or other specific disease, nor is it claiming to mitigate or cure that disease," lawyers assert. The comments were submitted in response to FDA's call for data on unreviewed drug products as part of the OTC safety review (1"The Tan Sheet" Jan. 5, 2004, p. 11)...
You may also be interested in...
FDA Issues Call For Data On Unreviewed OTCs To Complete Drug Review
FDA is requesting information on whether urinary analgesic/antiseptic products are appropriate for self-medication in a call for data on a range of products eligible for the OTC drug review. The notice was published in the Federal Register Dec. 31
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.
Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff
Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.